Wall Street Experts
ver. ZuMIgo(08/25)
Inozyme Pharma, Inc.
Rachunek Zysków i Strat
Przychody TTM (mln): 2
EBIT TTM (mln): -89
index |
0 |
1 |
2 |
3 |
4 |
5 |
6 |
Rok finansowy |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Przychód (mln) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Przychód Δ r/r |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
Marża brutto |
0.0% |
-inf% |
-inf% |
-inf% |
-inf% |
-inf% |
0.0% |
EBIT (mln) |
-12 |
-21 |
-57 |
-57 |
-69 |
-76 |
-104 |
EBIT Δ r/r |
0.0% |
79.5% |
174.2% |
-0.7% |
21.2% |
10.1% |
37.5% |
EBIT (%) |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
Koszty finansowe (mln) |
0 |
0 |
0 |
0 |
-2 |
3 |
-6 |
EBITDA (mln) |
-12 |
-21 |
-57 |
-56 |
-69 |
-74 |
-104 |
EBITDA(%) |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
Podatek (mln) |
5 |
-1 |
-1 |
-0 |
-2 |
0 |
0 |
Zysk Netto (mln) |
-7 |
-19 |
-56 |
-56 |
-65 |
-71 |
-102 |
Zysk netto Δ r/r |
0.0% |
167.3% |
199.9% |
1.0% |
16.0% |
8.7% |
43.4% |
Zysk netto (%) |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
EPS |
-0.46 |
-0.8 |
-2.39 |
-2.39 |
-1.73 |
-1.37 |
-1.62 |
EPS (rozwodnione) |
-0.46 |
-0.8 |
-2.39 |
-2.39 |
-1.73 |
-1.37 |
-1.62 |
Ilośc akcji (mln) |
15 |
23 |
23 |
24 |
38 |
52 |
63 |
Ważona ilośc akcji (mln) |
15 |
23 |
23 |
24 |
38 |
52 |
63 |
Waluta |
USD |
USD |
USD |
USD |
USD |
USD |
USD |